Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) Assets Average (2024 - 2026)

Prelude Therapeutics' Assets Average history spans 3 years, with the latest figure at $130.5 million for Q1 2026.

  • On a quarterly basis, Assets Average fell 17.62% to $130.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $130.5 million, a 17.62% decrease, with the full-year FY2025 number at $158.4 million, down 30.09% from a year prior.
  • Assets Average hit $130.5 million in Q1 2026 for Prelude Therapeutics, up from $118.0 million in the prior quarter.
  • Over the last five years, Assets Average for PRLD hit a ceiling of $262.4 million in Q1 2024 and a floor of $104.8 million in Q3 2025.
  • Historically, Assets Average has averaged $170.6 million across 3 years, with a median of $158.4 million in 2025.
  • Biggest five-year swings in Assets Average: plummeted 50.26% in 2025 and later fell 17.62% in 2026.
  • Tracing PRLD's Assets Average over 3 years: stood at $186.4 million in 2024, then plummeted by 36.67% to $118.0 million in 2025, then rose by 10.54% to $130.5 million in 2026.
  • Business Quant data shows Assets Average for PRLD at $130.5 million in Q1 2026, $118.0 million in Q4 2025, and $104.8 million in Q3 2025.